Sareum Holdings PLC New SRA737 preclin data to be presented at AACR (4053R)
February 28 2019 - 3:14AM
UK Regulatory
TIDMSAR
RNS Number : 4053R
Sareum Holdings PLC
28 February 2019
(AIM: SAR) 28 February 2019
Sareum Holdings plc
("Sareum" or "the Company")
Sareum notes that an abstract reporting new preclinical data for
SRA737 has been selected as a late-breaking oral presentation at
AACR 2019
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, notes that Sierra Oncology ("Sierra"),
the licence holder advancing clinical cancer candidate SRA737,
announced late yesterday that an abstract reporting preclinical
data for SRA737, its Chk1 inhibitor, plus low dose gemcitabine
(LDG), in combination with immunotherapy, has been selected for a
late-breaking oral presentation at the American Association of
Cancer Research (AACR) Annual Meeting 2019, to be held in Atlanta,
GA, USA from 29 March to 3 April 2019.
A late-breaking abstract details highly significant and timely
findings in any area of cancer research that were not available at
the time of the regular abstract deadline. Only those abstracts
that are deemed to be of high scientific priority will be accepted
for presentation at the meeting.
Commenting in the Sierra announcement, Dr. Lauren Byers,
Associate Professor at the University of Texas MD Anderson Cancer
Center, Houston, Texas, said: "We previously reported that SRA737
activated the innate immune signalling STING pathway and
demonstrated significant synergistic anti-tumour activity with
immunotherapy in an immunotherapy-refractory small cell lung cancer
(SCLC) model. SRA737 + LDG is a novel drug combination, where
gemcitabine acts as a potent inducer of replication stress that
potentiates SRA737's activity. These new studies reveal a striking
immunomodulatory effect of SRA737 + LDG that results in some of the
most profound synergistic activity with anti-PD-L1 therapy that we
have observed in this model. We are excited by the potential
clinical translatability of these findings and their possible
broader impact on immune checkpoint blockade strategies."
Dr. Christian Hassig, Chief Scientific Officer, Sierra Oncology,
added: "The dramatic enhancement of immunotherapy anti-tumour
activity in combination with SRA737 + LDG provides a strong
preclinical rationale for the potential of this replication stress
targeting strategy to broaden the limited clinical efficacy of
immunotherapy observed in certain cancers, such as SCLC."
The full announcement can be found by clicking here
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have
roles in pro-inflammatory responses in autoimmune diseases (e.g.
psoriasis, rheumatoid arthritis, inflammatory bowel diseases and
lupus) and tumour cell proliferation in certain cancers (e.g.
T-cell acute lymphoblastic leukaemia and some solid tumours). The
Company is targeting first human clinical trials in each indication
in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGIGDDDBDBGCI
(END) Dow Jones Newswires
February 28, 2019 03:14 ET (08:14 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024